Amanta Healthcare IPO Opens Today: ₹37.8 Crore Anchor Allocation, Key Strengths and Risks for Investors

New Delhi, September 1, 2025 – Amanta Healthcare Limited’s initial public offering (IPO) opened today. The issue, priced at a band of ₹120–₹126 per share, comprises 1 crore equity shares aggregating to ₹126 crore and closes on September 3, 2025. The listing is proposed on NSE and BSE.

Before Amanta Healthcare IPO, the company raised ₹37.8 crore from anchor investors by issuing 30,00,000 shares at a price of ₹126 per share. The anchor book saw interest from six investors, namely Bandhan Small Cap Fund, Sanshi Fund-1, Perpetuity H2W Rising Fund, Aarth Growth Fund, Sunrise Investment Opportunities Fund, and Finavenue Growth Fund.

Established in 1994, Amanta Healthcare Limited produces sterile liquid pharma products, mainly Large and Small Volume Parenterals. The IPO is its first foray into the capital markets, with listing expected on both NSE and BSE.

Anchor Investor Allocation

The firm issued a total of 30 lakh equity shares to six anchor investors, raising approximately ₹37.80 crore at an allocation price of ₹126 per share. Bandhan Small Cap Fund was the biggest participant, acquiring 7,93,730 shares, which represented 26.46% of the anchor portion and an investment of ₹10 crore. Sanshi Fund-1 subscribed for 5,95,010 shares, representing 19.83% of the allotment, worth ₹7.5 crore. Perpetuity Health to Wealth (H2W) Rising Fund got 4,20,665 shares or 14.02% which equals ₹5.3 crore. Aarth Growth Fund, Sunrise Investment Opportunities Fund, and Finavenue Growth Fund each got 3,96,865 shares, which is equivalent to 13.23% each, with an investment of ₹5 crore each.

Among these, Bandhan Small Cap Fund, a domestic mutual fund, got 26.46% of the anchor component.

Key Strengths

• Strong Presence in Manufacturing Sector: The firm has a robust manufacturing presence in Gujarat with state-of-the-art Blow Fill Seal (BFS) and ISBM technology.
• Diverse Portfolio in Healthcare: Amanta Healthcare’s portfolio comprises large and small volume parenterals in several therapeutic categories like ophthalmic, respiratory care, fluid therapy, and diluents.
• Global Presence: It also has an international presence, exporting to over 47 countries, with overseas markets generating over one-third of its revenues.

Key Risks

• Regulatory Exposure: Operations are subject to rigorous inspections by domestic and international regulators; failure to comply can result in sanctions or suspension.
• History of FDA Scrutiny: The predecessor company had been subject to negative observations in a 2013 FDA inspection, evidencing compliance sensitivity.
• Foreign Exchange Volatility: Given more than 33% of revenues from exports, profitability is sensitive to foreign exchange fluctuations.
• Competitive Landscape: Presence of several Indian and multinational players would put pressure on pricing and compress margins.

Disclaimer: At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.

If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.

Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations